Indian Pharmaceutical Market
- All
- News
- Videos
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
India-US Trade Pact To Open $30 Trillion Market For Indian Exporters: Piyush Goyal
The India-US trade pact will open a $30 trillion market for Indian exporters, especially MSMEs, farmers and fishermen, Commerce and Industry Minister Piyush Goyal said.
-
India's Top Export Markets: A Shifting Landscape Explained In Graphics
The United States on Monday slashed tariffs on Indian goods to 18 per cent, down from the previously effective rate of 50 per cent.
-
US Revives Drug Origin Debate, Cites Indian Exports
US renewed a push to require country-of-origin labeling on prescription drugs, citing temporary restrictions on pharmaceutical exports during the Covid pandemic by India as evidence that America's drug supply remains vulnerable to foreign disruptions
-
India-EU Trade Pact Explained: $572 Billion Boost To Indian Pharma, MedTech Industry
The India-EU Free Trade Agreement opens access to the European Union's $572.3 billion pharmaceuticals and medical devices market, boosting India's pharma sector, employment, MSMEs and global supply chain integration, according to the government.
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
New Study Highlights Drug Pricing And Regulation Issues In India
A new government study exposes serious flaws in India's drug pricing and regulation infrastructure. This study reveals how systemic failures impact drug pricing.
-
Trump May Exclude Generic Drugs From Tariffs. Good News For India?
The Donald Trump administration has dropped plans to impose tariffs on generic drugs from foreign countries, following months of debate over whether to impose taxes on the majority of medications prescribed in the US.
-
Trump's 100% Tariff On Pharma Will Not Impact Generic Makers: Industry Leaders
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
-
Trump Declares 100% Tariff On Pharma Imports From October 1, India May Be Hit
US President Donald Trump has announced tariffs of up to 100 per cent on imports of branded and patented pharmaceutical products from October 1. India's pharmaceuticals sector, one of the most dependent domestic industries on trade with America.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
India-US Trade Pact To Open $30 Trillion Market For Indian Exporters: Piyush Goyal
The India-US trade pact will open a $30 trillion market for Indian exporters, especially MSMEs, farmers and fishermen, Commerce and Industry Minister Piyush Goyal said.
-
India's Top Export Markets: A Shifting Landscape Explained In Graphics
The United States on Monday slashed tariffs on Indian goods to 18 per cent, down from the previously effective rate of 50 per cent.
-
US Revives Drug Origin Debate, Cites Indian Exports
US renewed a push to require country-of-origin labeling on prescription drugs, citing temporary restrictions on pharmaceutical exports during the Covid pandemic by India as evidence that America's drug supply remains vulnerable to foreign disruptions
-
India-EU Trade Pact Explained: $572 Billion Boost To Indian Pharma, MedTech Industry
The India-EU Free Trade Agreement opens access to the European Union's $572.3 billion pharmaceuticals and medical devices market, boosting India's pharma sector, employment, MSMEs and global supply chain integration, according to the government.
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
New Study Highlights Drug Pricing And Regulation Issues In India
A new government study exposes serious flaws in India's drug pricing and regulation infrastructure. This study reveals how systemic failures impact drug pricing.
-
Trump May Exclude Generic Drugs From Tariffs. Good News For India?
The Donald Trump administration has dropped plans to impose tariffs on generic drugs from foreign countries, following months of debate over whether to impose taxes on the majority of medications prescribed in the US.
-
Trump's 100% Tariff On Pharma Will Not Impact Generic Makers: Industry Leaders
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
-
Trump Declares 100% Tariff On Pharma Imports From October 1, India May Be Hit
US President Donald Trump has announced tariffs of up to 100 per cent on imports of branded and patented pharmaceutical products from October 1. India's pharmaceuticals sector, one of the most dependent domestic industries on trade with America.
